Actively Recruiting
Angiogenic Inflammatory Biomarkers in Juvenile Idiopathic Arthritis
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-09-12
300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
A
Assistance Publique - Hôpitaux de Paris
Lead Sponsor
U
URC-CIC Paris Descartes Necker Cochin
Collaborating Sponsor
AI-Summary
What this Trial Is About
Juvenile idiopathic arthritis (JIA) is a group of chronic inflammatory rheumatic diseases that start before age 16 and represent the most common pediatric rheumatologic condition. Researchers are studying whether certain serum inflammatory angiogenic markers, such as semaphorins and CCN1 protein, can predict the severity of JIA by assessing structural joint damage and treatment changes. This research builds on previous findings in rheumatoid arthritis where these markers were linked to disease activity and structural harm. The study observes patients with JIA who are followed in a specialized rheumatology consultation, without administering experimental treatments. Blood samples will be collected to measure angiogenic and inflammatory markers over five years. Joint punctures may be performed if required by routine care. Researchers will also gather data on treatments received, structural damage via X-rays, and patient questionnaires at various time points including at the start of the study. Participants will be involved in regular assessments over five years, including blood tests, questionnaires, and imaging to monitor disease progression and biomarker levels. The main focus is on measuring angiogenic and inflammatory markers using methods like ELISA to understand their association with disease severity. This long-term observation aims to improve prediction of JIA outcomes while ensuring patient care continues as usual throughout the study period.
CONDITIONS
Brief Title
Angiogenic Biomarkers in Juvenile Idiopathic Arthritis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 16 years or older
- Diagnosed with juvenile idiopathic arthritis and followed by rheumatology at Cochin Hospital
- No opposition to participation in the research
- Have health insurance
- Able to understand and speak French
You will not qualify if you...
- Under curatorship or guardianship
- Receiving French state medical aid
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants receive blood samples and joint punctures if needed according to routine care to study angiogenic and inflammatory biomarkers over time.
Regular visits during specialized rheumatology consultations over 5 years
Trial Site Locations
Total: 1 location
1
Rheumatology Department, Cochin Hospital
Paris, IDF, France, 75014
Actively Recruiting
Research Team
Y
Yannick ALLANORE, PD, PhD
M
Marie BENHAMMANI-GODARD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here